Methods: Patients <18 years of age and diagnosed with JIA in the Truven Health MarketScan^® database between July 1 2006 and September 30 2014 were eligible for inclusion in the analysis. Patients were required to have at least 180 days of continuous health plan enrollment prior to, and ≥1 day following, a diagnosis of JIA based on two International Classification of Diseases, Ninth Revision, Clinical Modification codes (714.3x) within 90 days. The abatacept cohort includes patients initiating abatacept or another bDMARD who may be initiating a biologic for the first time or switching from one biologic to another. Baseline characteristics including at least 15 co-morbid conditions and concomitant medications were captured within the 6-month period prior to the diagnosis of JIA. Results: A total of 13,602 patients with a diagnosis of JIA were identified in the US HCC database, with an average follow-up of 2.26 years (maximum 8.26 years); 343 abatacept users and 3507 users of other bDMARDs were identified. Overall, abatacept users were slightly older and more likely to have asthma and hypertension; other bDMARDs users were more likely to have uveitis reported in the 6-month baseline period. Corticosteroid use and outpatient visits were also higher in abatacept users.